Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions

Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now. Citizens JMP reaffirmed its Market Perform rating on Incyte Corporation (NASDAQ:INCY) on September 18 after the company revealed updated clinical trial findings for its medication povorcitinib. The company evaluated povorcitinib in patients with moderate-to-severe hidradenitis suppurativa in its pivotal Phase 3 STOP-HS1/HS2 trials, presenting 24-week data at the EADV 2025 Congress.

According to Citizens JMP, povorcitinib continues to show promise in a field that is becoming increasingly competitive, with Phase 3 trials in vitiligo, prurigo nodularis, and CSU currently underway.

Although the firm estimates that the approval of povorcitinib could result in peak revenues of $1 billion, it says that Incyte shares are fairly valued as it waits for a significant acquisition and pipeline discipline to balance the projected $3 billion+ ruxolitinib patent gap by 2029.

Incyte Corporation (NASDAQ:INCY), an American global pharmaceutical company, operates as a market leader in developing treatments for patients suffering from various diseases, including cancer.

While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.